Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats

Autor: Alberto Brugnoli, Clarissa Anna Pisanò, Michele Morari

Publikováno v: Neurobiology of Disease, Vol 144, Iss , Pp 105044- (2020)

Acetylcholine muscarinic receptors (mAChRs) contribute to both the facilitation and inhibition of levodopa-induced dyskinesia operated by striatal cholinergic interneurons, although the receptor subtypes involved remain elusive. Cholinergic afferents

Externí odkaz: https://doaj.org/article/baa2add88b2b4381b0a823f7bffc5faf

Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats

Autor: Michele Morari, Clarissa Anna Pisanò, Alberto Brugnoli

Publikováno v: Neurobiology of Disease, Vol 144, Iss, Pp 105044-(2020)

Acetylcholine muscarinic receptors (mAChRs) contribute to both the facilitation and inhibition of levodopa-induced dyskinesia operated by striatal cholinergic interneurons, although the receptor subtypes involved remain elusive. Cholinergic afferents

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b75c3e35a7143c77cd5d1a95799653b
http://www.sciencedirect.com/science/article/pii/S0969996120303193

6-Hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulata

Autor: Clarissa Anna Pisanò, Harkaitz Bengoetxea, Catalina Requejo, Michele Morari, José Vicente Lafuente, Cristina Miguelez, Luisa Ugedo, Sergio Vegas-Suarez

Publikováno v: Addi: Archivo Digital para la Docencia y la Investigación
Universidad del País Vasco
British Journal of Pharmacology
Addi. Archivo Digital para la Docencia y la Investigación
instname

Background and Purpose l-DOPA-induced dyskinesia (LID) is considered a major complication in the treatment of Parkinson's disease (PD). Buspirone (5-HT(1A)partial agonist) have shown promising results in the treatment of PD and LID, however no 5-HT-b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c62193f03edfecb32d5e9376e90812d4
http://hdl.handle.net/11392/2471960

Leucine-rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes

Autor: Clarissa Anna Pisanò, Paolo Bolognesi, Michele Morari, Francesco Longo, Derya R. Shimshek, Martina Frassineti, Daniela Mercatelli

Publikováno v: Pharmacology Research & Perspectives

Mutations in leucine‐rich repeat kinase 2 (LRRK2) gene have been pathogenically linked to Parkinson's disease, and pharmacological inhibition of LRRK2 is being pursued to tackle nigro‐striatal dopaminergic neurodegeneration. However, LRRK2 kinase

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::504baad34213bfdd3d41de104bfa6efa
https://pubmed.ncbi.nlm.nih.gov/31149340

NOP receptor ligands and Parkinson’s disease

Autor: Michele Morari, Clarissa Anna Pisanò, Salvatore Novello, Daniela Mercatelli

Publikováno v: Handbook of Experimental Pharmacology ISBN: 9783030201852

Nociceptin/Orphanin FQ (N/OFQ) and its NOP receptor are highly expressed in motor areas of the rodent, nonhuman, and human primate brain, such as primary motor cortex, thalamus, globus pallidus, striatum, and substantia nigra. Endogenous N/OFQ negati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::774cbb9bca92a7529d2adef95118c8a8
http://hdl.handle.net/11392/2411797